AR and prostate carcinoma: Another explanation on higher IC50s seen in GBM cell lines is the potential presence of AR-Vs, as discussed above that may render GBM cells much more resistant to AR antagonists comparing to androgen-dependent prostate cancer cells, which will keep us in mind when developing future clinical trials repurposing AR antagonists for GBM treatment.